Fate Therapeutics (FATE)
(Delayed Data from NSDQ)
$3.89 USD
+0.28 (7.76%)
Updated Jul 15, 2024 04:00 PM ET
After-Market: $3.90 +0.01 (0.26%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth F Momentum F VGM
Brokerage Reports
Fate Therapeutics, Inc. [FATE]
Reports for Purchase
Showing records 321 - 340 ( 439 total )
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
MORNING CALL
Provider: WEDBUSH SECURITIES INC.
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Initial Look at VOYAGE Encouraging, ProTmune at ASH
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Early Encouraging Data With FATE-NK 100 in r/r AML at SITC
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Biotechnology - SITC Meeting Preview for Covered Companies
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
MORNING CALL
Provider: WEDBUSH SECURITIES INC.
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
3Q, Upcoming Presentations Should De-Risk Early Stage Programs
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
3Q17: ProTmune Data Expected at ASH; Reiterate Buy and $7 Price Target
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
HEALTHCARE - The Week Ahead in Life Sciences
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Putting Our Faith in Fate Therapeutics; Assuming Coverage With Buy Rating and $7 Price Target
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Ph 2 PROTECT Preview: Looking Ahead at ASH for Major Value Inflection
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
HEALTHCARE - 2017 PacGrow Healthcare Conference: Day 2 Recap
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
MORNING CALL
Provider: WEDBUSH SECURITIES INC.
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
2Q, ProTmune and NK100 Programs Making Progress
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences: Upcoming Events for the Week of July 31
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences: Upcoming Events for the Week of July 24
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Biotechnology - The Week Ahead in Life Sciences: Upcoming Events for the Week of July 10
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences: Upcoming Events for the Week of July 3
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences: Upcoming Events for the Week of June 26
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D